{
    "organizations": [],
    "uuid": "2d8d8367b33b16c380b57047ac56ab8b90b96890",
    "author": "",
    "url": "https://www.reuters.com/article/brief-thrombogenics-initiates-phase-2-cl/brief-thrombogenics-initiates-phase-2-clinical-study-for-treatment-of-diabetic-macular-edema-idUSFWN1S4040",
    "ord_in_thread": 0,
    "title": "BRIEF-Thrombogenics Initiates Phase 2 Clinical Study For Treatment Of Diabetic Macular Edema",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 27 (Reuters) - THROMBOGENICS NV:\n* THROMBOGENICS INITIATES PHASE 2 CLINICAL STUDY EVALUATING ANTI-PLGF (THR-317) IN COMBINATION WITH ANTI-VEGF (RANIBIZUMAB) FOR TREATMENT OF DIABETIC MACULAR EDEMA (DME)\n* INITIAL RESULTS FROM THR-317-002 STUDY ARE ANTICIPATED IN Q3 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-27T08:55:00.000+03:00",
    "crawled": "2018-04-27T09:13:50.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "thrombogenics",
        "nv",
        "thrombogenics",
        "initiate",
        "phase",
        "clinical",
        "study",
        "evaluating",
        "combination",
        "ranibizumab",
        "treatment",
        "diabetic",
        "macular",
        "edema",
        "dme",
        "initial",
        "result",
        "study",
        "anticipated",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}